Noticias

Zacks3d agoneutral

Here's Why You Should Add Pediatrix Medical to Your Portfolio Now

MD gains from stronger cash collections, payer mix and acquisitions, while telehealth expansion and buybacks support growth.

StockStory3d agobullish

1 Cash-Heavy Stock on Our Buy List and 2 We Find Risky

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.

Zacks4d agoneutral

RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay

Revvity gains FDA clearance for IDS' Total Testosterone assay, expanding its automated endocrine testing platform for reproductive diagnostics.

WST

Zacks4d agobearish

Doximity Stock Falls on Q4 Earnings Miss, Revenues Beat, Margins Down

DOCS' revenues top estimates as AI tool adoption and large customer growth fuel engagement despite weaker earnings and margin pressure.

WST

Zacks4d agoneutral

Reasons to Hold HealthEquity Stock in Your Portfolio for Now

HQY rides on strong HSA growth, AI-driven efficiency gains and solid Q4 results, though data security threats remain a key risk.

WST

Cybersecurity Dive4d agoneutral

West Pharmaceutical starts restoring operations after ransomware attack

The company confirmed data was stolen and encrypted by the attackers.

PANW WST

Zacks5d agobullish

VEEV Boosts MedTech Quality Management With Smith+Nephew Partnership

Veeva Systems expands its medtech reach as Smith+Nephew adopts Veeva Quality Cloud to modernize global quality operations and training.

VEEV WST

Zacks5d agobullish

NPCE Stock Gains on Q1 Earnings & Revenue Beat, 2026 Outlook Raised

NeuroPace raises revenue guidance for 2026 after Q1 sales beat estimates and losses narrow, driven by strong RNS System growth.

WST

Simply Wall St.5d agoneutral

Does West Pharmaceutical’s Rejected Independent Chair Proposal Reflect a Stable Governance Edge for WST?

On May 4, 2026, West Pharmaceutical Services held its annual general meeting, where shareholders voted against a proposal to require an independent board chair policy. This governance outcome comes as the company has recently delivered earnings above consensus expectations, reinforcing the influence of financial performance on investor voting behavior. Against this backdrop of robust recent earnings surprises, we'll examine how the board chair vote outcome may reshape West Pharmaceutical's...

WST